Willis Towers Watson stock trades close to 52-week high as analysts lift forecasts

Willis Towers Watson Public Limited Company (ISIN GB00BGSZ2X45) stock is trading close to its recent 52-week high as of August 21, 2026, while analysts project double-digit earnings growth and see further upside to the current share price.

Analyst forecasts point to EPS growth

Recent analyst data compiled on August 21, 2026 indicates that Willis Towers Watson is expected to deliver earnings per share of $19.77 in 2026 and $22.57 in 2027, which represents year-over-year growth of 15.8 percent for 2026 and 14.1 percent for 2027 according to a consensus overview. These figures underline that profit expectations are rising at a solid double-digit pace and that analysts anticipate continued expansion in the company’s bottom line over the next two fiscal years.

Alongside these earnings projections, a group of equities research analysts has set an average 12-month stock price forecast for Willis Towers Watson at $369.38 per share, with individual targets ranging from $300.00 to $455.00. This range shows that while some analysts take a more cautious stance, others see room for the stock to trade significantly above its current level based on the company’s earnings profile and business outlook.

On August 21, 2026, one report highlighted that the consensus rating on Willis Towers Watson is described as a moderate buy, reflecting that most covering analysts remain positive on the shares but with an eye on valuation and sector risks. For retail investors, the combination of forecast earnings growth near the mid-teens and a supportive, though not unanimous, analyst stance gives a quantifiable sense of how the professional community views the stock’s risk-reward balance.

Shares trade close to 52-week high with upside to targets

Market data as of August 21, 2026 shows Willis Towers Watson stock trading close to its 52-week high of $344.14 per share, with a recent closing level reported at $335.46 per share. This places the shares only single-digit dollars below the high of the last 12 months, signaling that investors have already priced in a substantial part of the company’s recent progress and that the stock is viewed favorably relative to its trading history over the past year.

An additional snapshot of the stock’s trading performance notes that Willis Towers Watson opened one recent Nasdaq session at $341.15 per share, underlining that the shares have been fluctuating within a relatively tight band around the low $340s. That price zone matters because it sits close to both the 52-week high and the average analyst price target, providing a concrete technical and fundamental reference range for investors tracking short-term moves.

Against the current trading band, the average analyst price target of $369.38 per share implies upside of around the low-teens percentage from levels in the low-to-mid $340s. At the same time, one of the more optimistic published targets at $455.00 would, if reached, position the shares substantially above both the current price and the 52-week high, illustrating how bullish scenarios assume that the company can sustain its forecast earnings growth and navigate sector challenges.

Health-cost inflation and benefits consulting backdrop

Sector commentary dated August 21, 2026 emphasizes that health-care cost inflation remains elevated across major markets, creating persistent pressure on employers, insurers, and public systems. In this environment, Willis Towers Watson’s benefits consulting, brokerage, and data-driven advisory services are a key part of how corporate clients seek to manage rising medical and benefits expenses while maintaining workforce coverage.

One sector-focused article notes that health-cost pressures are not expected to ease quickly, which means demand for sophisticated benefits design, actuarial analysis, and risk management solutions is likely to remain structurally strong. For Willis Towers Watson, this backdrop supports the company’s consulting pipeline and fee-based revenue streams, as clients look to recalibrate plan designs, contribution structures, and wellness initiatives in response to higher per-employee health spending.

In addition, the same sector context places Willis Towers Watson alongside other large health and benefits players that are adjusting strategies to address inflation, regulatory changes, and evolving employer needs. While this intensifies competitive dynamics, it also underscores the scale of the addressable market for advisory and technology-enabled solutions that help clients forecast and contain their benefits cost trajectory.

Integrated people, risk, and capital strategy

A corporate update highlighted on August 20, 2026 discusses the firm’s integrated people, risk, and capital strategy and leadership responsibilities related to that framework. The dual role described in that update reflects Willis Towers Watson’s effort to align its human capital advisory services with broader risk and capital management capabilities, reinforcing the idea that workforce-related decisions are closely linked to balance-sheet strength and long-term financial resilience.

By connecting employee benefits, rewards, and talent strategies with enterprise risk management and capital allocation, Willis Towers Watson aims to offer clients a more holistic advisory model. This integrated approach is designed to help companies understand how decisions on pensions, health plans, and compensation structures interact with risk metrics, funding requirements, and shareholder expectations.

For investors, this leadership and strategy narrative matters because it suggests that Willis Towers Watson is positioning itself not only as a benefits consultant but as a multi-line adviser that can support board-level decisions on people, risk, and capital. The ability to cross-sell services and maintain deep, multi-year client relationships can be a driver of recurring revenues and margin stability, which aligns with the earnings growth forecasts cited earlier.

Representative product: benefits consulting services

One representative pillar of Willis Towers Watson’s business is its benefits consulting offering, which encompasses advisory work on employer-sponsored health plans, retirement and pension schemes, and other employee benefits structures. Through these consulting services, the company helps clients design and implement plans that balance workforce needs, regulatory compliance, and cost-management objectives, drawing on actuarial expertise and benchmarking data.

These benefits consulting engagements often involve modeling different plan structures, projecting long-term cost trajectories, and assessing the impact of changes in demographics, utilization patterns, or medical inflation. For employers facing higher health-care costs and tightening labor markets, such services are a critical tool in maintaining competitive offerings without putting undue pressure on operating margins or cash flow.

In addition to plan design, Willis Towers Watson’s benefits consultants typically support clients in vendor selection, contract negotiations, and performance monitoring for insurers and administrators. This end-to-end support is part of how the company embeds itself in clients’ ongoing benefits governance processes, which can reinforce long-term relationships and support the recurring revenue base that underpins analysts’ multi-year earnings forecasts.

Stock level and investor takeaway

As of August 21, 2026, Willis Towers Watson stock is trading on Nasdaq in the mid-$330s to low-$340s range, with recent data citing levels such as $335.46 and $341.15 per share in relation to a 52-week high of $344.14. This positioning just below the 12-month peak, combined with consensus earnings growth of 15.8 percent in 2026 and 14.1 percent in 2027 and an average price target of $369.38, gives investors a quantified framework for assessing whether the current valuation fairly reflects the company’s growth prospects in a high health-cost environment.